Beauty1,0401,0114,1144,240Essential Health1,1481,0824,6324,688Total segment net sales$3,780$3,662$15,124$15,455ExpandSegment Adjusted operating income for the periods presented was as follows:Adjusted Operating IncomeFiscal Three Months EndedFiscal Twelve Months Ended(Unaudited; Dollars in Millions)December 28,2025December 29,2024December 28,2025December 29,2024Self Care Adjusted operating income$496$481$2,109$2,173Skin Health and Beauty Adjusted operating income99105477607Essential Health Adjusted operatin ...

Group 1 - Kenvue Inc. will announce its fourth quarter and full year 2025 financial results on February 17, 2026, after market close [1] - Kenvue will not host a quarterly conference call due to a pending transaction with Kimberly-Clark [1] - The press release regarding the financial results will be available on the company's investor website [1] Group 2 - Kenvue Inc. is the world's largest pure-play consumer health company by revenue [2] - The company has a heritage of over a century and features iconic brands such as Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena®, and Tylenol® [2] - Kenvue emphasizes the importance of everyday care and aims to empower consumers through its products [2]

Core Insights - Frontier AI company Albert Invent has formed a strategic partnership with Kenvue Inc. to enhance R&D efforts across Kenvue's global brand portfolio [1] Group 1: Partnership Details - The partnership aims to streamline, digitalize, and accelerate the end-to-end product lifecycle for Kenvue's consumer health products [1] - Kenvue is known for its brands such as Zyrtec®, Neutrogena®, and Listerine® [1] Group 2: Technological Integration - Albert Invent will leverage its foundational AI models to support Kenvue in its R&D initiatives [1]